BioSpace News Archive

Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced a $50 million investment by NVIDIA, which was executed as a private investment in public equity (PIPE).

Cryoport, Inc., a leading global provider of innovative products and services for the fast growing cell and gene therapy industry, announced certain preliminary results for second quarter 2023 and updated its expectations for full year 2023 revenue expectations.

Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, will release its financial results for the second quarter 2023, after market close on Tuesday, August 1, 2023.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will report financial results for the second quarter of 2023 after market close on Thursday, August 3, 2023.

89bio, Inc. announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 2,600 shares of the Company’s common stock to one new employee on the later of July 6, 2023 and the employee’s commencement of employment with the Company.

Burjeel Holdings and BridgeBio Pharma, Inc. have announced a new project to revolutionize the field of early diagnosis and treatment of rare diseases or disorders in the UAE and the region.

Psychemedics Corporation, the world’s largest provider of hair testing for drugs of abuse, announced that its board of directors has approved a transition plan for the Company’s President and CEO position.

Bicycle Therapeutics plc announced the pricing of an underwritten public offering of 9,411,766 American Depositary Shares, each representing one ordinary share and, in lieu of ADSs to investors that so choose, non-voting ordinary shares, each at a price to the public of $21.25 per share, for gross proceeds of approximately $200.0 million.

Direct Biologics Announces Publication of Significant Survival Benefit with ExoFlo ™ in its Phase 2 Randomized Controlled Clinical Trial in the Journal CHEST.

Seagen Inc. (Nasdaq: SGEN) today announced that it will report its second quarter 2023 financial results on Wednesday, August 2, 2023.